



Gregory J. Nickels
Mayor of Seattle

December 16, 2004

Dr. Paul Ramsey
Vice President for Medical Affairs and
Dean of the School of Medicine
University of Washington
Box 356350
Seattle WA 98195

Dear Dr Ramsey:


I am pleased to offer this letter of support for the University of Washington, School of Medicine's application for a National Institutes of Health Regional Bio-containment Laboratory (RBL) Construction Program grant in the amount of \$25 million dollars.

The University of Washington is the City's largest employer with a daily population of over 65,000 people and over 1 billion dollars in annual research grants. My administration has successfully worked with the University and the community to change City regulations which enable the University to continue as the City's engine of economic opportunity. To that end, my administration and our City's Department of Design and Planning stand ready to assist the University in their efforts to design and construct a Regional Bio-Containment Laboratory (RBL) on the Seattle campus.

Currently, there is a shortage of such facilities and an RBL in our region would enhance our ability to contribute to the development of new antibiotics and vaccines that will protect our citizens from harm and make a major contribution in the arena of global health.

Thank you for your consideration.

Sincerely,



GREG NICKELS
Mayor of Seattle

cc: ✓ Theresa Doherty, Assistant VP Regional Affairs U of W





FRED
HUTCHINSON
CANCER
RESEARCH
CENTER

Advancing Knowledge, Saving Lives
Lee Hartwell, Ph.D.
President and Director
Ph: 206-667-5670 Fax: 206-667-5268

RECEIVED

DEC 7 1 2004

VICE PRESIDENT FOR MEDICAL AFFAIRS
DEAN SCHOOL OF MEDICINE

December 20, 2004

Paul G. Ramsey, M.D., Vice President for Medical Affairs and Dean
School of Medicine
University of Washington
Box 356350
Seattle, WA 98195

RE: Regional BioContainment Laboratory


Dear Paul:

I strongly support the University of Washington, School of Medicine's application for a National Institutes of Health Regional Biocontainment Laboratory (RBL) Construction Program grant. The School of Medicine serves a five state region including Alaska, Idaho, Montana, Washington and Wyoming. The region represents approximately 25% of the land mass of the United States. This BSL-2 and BSL-3 facility would provide research opportunities for the entire region in the development of new vaccines, diagnostic tools and procedures, and advancement in finding antibiotics for NIAID category A,B and C pathogens and emerging infectious diseases. The University of Washington is a National Institute for Allergy and Infectious Disease (NIAID) Regional Center of Excellence for Biodefense and Emerging Infectious Diseases but without the dedicated facility it is limited in what it can accomplish. In addition, this type of facility should also facilitate some of the long-standing research collaborations between the Fred Hutchinson Cancer Research Center and the University of Washington.

In addition, this facility would be part of the NIAID biodefense network. In the event of a bioterrorism attack or outbreak of an emerging infectious disease, all of the resources of this facility would be available and prepared to assist national, regional and local public health efforts.

The research and development outcomes from such a facility would have a significant impact on global health.

Sincerely,


Lee Hartwell, Ph.D.

December 13, 2004

Karen L. Hedine
President/CEO
PH: (425)895-9197, x 126

Paul G. Ramsey, M.D.
Vice President for Medical Affairs and
Dean of the School of Medicine
University of Washington
Box 356350\nc-314, Health Sciences Center
Seattle, WA 98195-6350

Re: Letter of Support: RFA A1-04-032

Dear Dr. Ramsey:


Micronics, Inc., a Washington-state business and leading provider of laboratory-on-a-card devices on behalf of clients worldwide, is pleased to write this letter of support for the University of Washington regarding construction of a Regional Biocontainment Laboratory.

Micronics is partnered with leading researchers at the University of Washington and elsewhere in response to several homeland defense and emerging disease initiatives. As such, we support the construction locally of a facility that could benefit the scientific and public health communities' efforts in advancing research and product development and providing timely response in the event of a bioterrorism emergency.

Access to a regional resource center of this nature would also be tremendously beneficial to researchers in industry, both locally, throughout the state and nationally, that are committed to working with companies like ours to advance small, deployable, user friendly and cost effective devices for biothreat and emerging disease detection, diagnosis and monitoring.

We believe that the University of Washington's outstanding reputation as a leading research institution that has been responsible for medical and scientific breakthroughs that are highly responsive to user needs, and its record of generating countless cutting edge technologies, such as those licensed to Micronics, makes it an ideal recipient of the funding for this facility.

Best regards,



Karen L. Hedine

December 20, 2004

RECEIVED

DEC 27 2004

Paul G Ramsey, MD
Vice Pres. for Medical Affairs
Dean, University of Washington School of Medicine
C-314, Health Sciences Center
FAX: +1 206 685-8767

VICE PRESIDENT FOR MEDICAL AFFAIRS
DEAN SCHOOL OF MEDICINE


RE: RFA-AI-04-032

Dear Paul:

I'm writing in support of the UWSOM application to establish a Regional Biocontainment Laboratory on campus. Our programs at the Benaroya Research Institute cover a range of applications in human immunity and vaccine research, including the recent award of an NIAID contract for an epitope discovery program focused on category A, B and C pathogens and emerging infectious diseases. A dedicated BSL-2 and BSL-3 RBL facility at the UW would be a great asset, both to our existing programs and to enhance future collaborations between our institutions.

Clearly, this is an important regional opportunity to expand capability in infectious disease research, biodefense, and national security. The lack of a facility in the region now necessarily limits the scope of current work, and limits our preparedness for unforeseen needs. The BRI, as you know, is a regional center of excellence for human immunity research, and we are enthusiastic about strengthening our collaborations with the UW and RBL investigators through utilization of the facility and the national research network that will be created. This facility would greatly assist in linking our programs in vaccine research with priority RBL projects, and with regional biotechnology interests in infectious disease research

Very truly yours,


Gerald T. Nepom, MD PhD
Director



Advancing Global Health Through Discovery™

December 20, 2004

RECEIVED

Paul Ramsey, M.D.,
Vice Pres. for Medical Affairs & Dean of Medicine
University of Washington
School of Medicine
Box 356350
Seattle, WA 98195-6350

DEC 27 2004

VICE PRESIDENT FOR MEDICAL AFFAIRS
DEAN SCHOOL OF MEDICINE

Re: Application in response to NIH RFA-AI-04-032


Dear Dean Ramsey,

On behalf of Seattle Biomedical Research Institute (SBRI), I am pleased to indicate SBRI's strongest support for the funding and construction of a Regional Biocontainment Laboratory (RBL) with BSL-2 and BSL-3 facilities near the Health Sciences Center on the University of Washington campus.

The importance of such a building and the benefits to this region are obvious. Moreover, the University of Washington's School of Medicine is the best possible manager of such a regional resource over the long term. Such a building would help address the national and regional shortage of facilities for work with category A, B and C pathogens and emerging infectious diseases. A state of the art, stand-alone facility dedicated to biodefense and emerging infectious diseases will be an important regional resource for its research institutions. It will provide an expanded capability for infectious disease research in this area, create new opportunities for increased collaborations in infectious disease research, and promote the development of important new research programs. Indeed the mechanisms for short-term utilization of the facility through collaboration with RBL investigators will stimulate these developments. Furthermore, the existing program of the WAMI Regional Center of Excellence in Biodefense for developing research and education projects throughout the region already provides a functioning model for these expanded activities.

The unique facilities provided by the RBL will strengthen regional security and catalyze biotechnology research in vaccines, diagnostics, and antibiotics for infectious disease research. It will promote the development of new therapeutics and vaccines that are needed to protect the United States and to improve global health, including that in developing countries. It is both comforting and important that the RBL will function as part of a national network not only to assist the national government in achieving its research objectives but also that it will be available for response to a national or regional emergency related to bioterrorism or emerging infectious diseases.

Sincerely,



Kenneth Stuart, PhD
President and Director

Cc: Jim Gore

307 Westlake Ave N Suite 500
Seattle, WA 98109-5219

T 206.256.7200

F 206.256.7229

W www.sbri.org

173A

ZYMOGENETICS

December 21, 2004

RECEIVED

DEC 22 2004

Paul Ramsey, M.D.
University of Washington
1959 NE Pacific Street
HSB Room C-314
Box No. 356350
Seattle, WA 98195-6350

VICE PRESIDENT FOR MEDICAL AFFAIRS
DEAN SCHOOL OF MEDICINE

Dear Dr. Ramsey,


I strongly support the University of Washington's School of Medicine's application for a Regional Biocontainment Laboratory.

I believe that strong biomedical research at the University of Washington is the keystone to a healthy biotechnology industry in the State of Washington. Indeed, many biotechnology companies, including ZymoGenetics, owe their existence to research initiated at the University of Washington. I further believe that collaboration between the University of Washington and biotechnology companies benefit both parties and will benefit human health in many countries.

A Biocontainment Laboratory is critical if the University is to develop the much needed vaccines and drugs that we will need in this century to combat new diseases.

Infectious diseases are a worldwide problem but many people, at the turn of the millennium, predicted that one of the great dangers of this century would be the appearances of infectious diseases that are previously unknown in the United States.

Sincerely,



Bruce L.A. Carter, Ph.D.
President & CEO

BrCa/JaSt



Amgen
1201 Amgen Court West
Seattle, WA 98119-3105
206.265.7000 Ext. 58720
Fax: 206.216.5930
E-mail: rhassler@amgen.com

December 10, 2004

Paul Ramsey, M.D.
Vice President for Medical Affairs and Dean of the School of Medicine
University of Washington
1959 NE Pacific Street
Suite C-314, Health Sciences Center
Seattle, WA 98195-6340

Dr. Ramsey:

We at Amgen are in full support of the University of Washington School of Medicine's application for an NIH/NIAID grant to build a Regional Biocontainment Laboratory (RBL).

As a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics, we are committed to improving the lives of patients. Having an RBL in our region provides a unique opportunity to greatly expand research into infectious diseases – truly a complement to our mission.

We are also deeply committed to the scientific community in this area. We are fortunate to have a host of public and private institutions rich in science talent and energy. Having an RBL as a regional resource will no doubt catalyze collaboration and discovery among those leading researchers in the areas of vaccines, diagnostics, and antibiotics for infectious diseases.

We are pleased to back the University in this effort. The opportunity to provide important benefits to our national defense, to public health efforts, and to citizens here in the United States and around the world is one we should not miss.

Sincerely,

A handwritten signature in black ink that reads "R.A. Hassler". The signature is fluid and cursive, written over a white background.

Randal Hassler
Vice President for Amgen Washington Operations



RECEIVED

DEC 13 2004

VICE PRESIDENT FOR MEDICAL AFFAIRS
DEAN SCHOOL OF MEDICINE

A. Bruce Montgomery, M.D.
Chief Executive Officer

December 10, 2004

Paul G. Ramsey, MD
Vice President for Medical Affairs & Dean of the School of Medicine
C-314, Health Sciences Center
University of Washington School of Medicine
1959 NE Pacific Street, Box 356350
Seattle, WA 98195-6350
FAX: +1 206 685-8767

Dear Dr. Ramsey:

This is a letter of support for the UW School of Medicine application for NIH/NIAID-funded Regional Biocontainment Laboratory (RBL). An RBL will serve as a regional resource for research institutions in the area, and must be available and prepared to assist national, state and local public health efforts in the event of a bioterrorism emergency.

There is a shortage of such sites locally and nationally and this is an important regional opportunity to expand capability in infectious disease research. The RBL will provide unique facilities to promote the development of new antibiotics and vaccines that will protect the United States and make major contributions to global health, including developing countries.

A specific example from my company illustrates the need. A potential treatment or prophylaxis measure for anthrax inhalation exposure is the use of an aerosol antibiotic. Local delivery of high concentrations of potent antibiotics could be life saving. We are aware of currently approved antibiotics that might be much more effective if converted to an aerosol route of delivery. In spite of interest from DARPA and other Federal agencies, the shortage of an animal testing facility has made any proposal to proceed impossible. We have even investigated doing these studies in the United Kingdom without success.

Development of a local facility would likely lead to a cooperative program with academic researchers to test this concept.

Corus Pharma Inc.

2025 1st Avenue Suite 800 Seattle, WA 98121

Telephone: 206 728-5090 Fax 206 728-5095 www.coruspharma.com

The lack of animal testing facilities prevents testing of ideas that would be a near term value in the struggle to deal with bioterrorism. Over the longer term, early stage programs would not stall out due to a lack of animal testing facilities.

I support the UW School of Medicine application for NIH/NIAID-funded Regional Biocontainment Laboratory (RBL) without reservation.

Sincerely,

A handwritten signature in black ink that reads "A. Bruce Montgomery". The signature is written in a cursive, flowing style.

A. Bruce Montgomery MD